BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:LNPs continue to dominate the spotlight in biopharma with thre
 e landmark acquisitions in the past six months\, AbbVie/Capstan Therapeut
 ics\, Eli Lilly and Co/Verve Therapeutics and Bristol Myers Squibb/Orbita
 l Therapeutics. Validating LNPs as a stand-out delivery vehicle for cell 
 and gene therapies!\n\nReturning to Boston in April 2026\, the 5th LNP Fo
 rmulation and Process Development Summit is an industry-led end-to-end me
 eting providing the latest scientific content to advance LNP development 
 for a variety of payloads and therapeutic applications\, from mRNA vaccin
 es to next-generation cell and gene therapies. This is your one-stop shop
  to hear insights on LNP discovery\, analytics\, formulation\, process de
 velopment and large-scale manufacturing.\n\nWith 3 focused streams\, Anal
 ytical Development and Characterization\, Formulation and Delivery and Pr
 ocess Development and Manufacturing\, this is your opportunity to overcom
 e challenges in achieving precise extrahepatic delivery\, robust characte
 rization of targeted LNPs and optimal formulations for ambient storage\, 
 all towards making LNP drug products more selective\, safe and potent.\n\
 nUniting 250+ global LNP trailblazers\, gain exclusive access to LNP spec
 ific networking\, partnership opportunities and collaborative discussions
  to drive the next-generation of LNPs towards the clinic.\n\nURLs:Tickets
 : https://go.evvnt.com/3347173-2?pid=185Brochure: https://go.evvnt.com/33
 47173-3?pid=185\n\nDate and Time: On Mon\, 06 Apr 2026 08:00 - Wed\, 08 A
 pr 2026 17:00\n\nCategory: Conferences | Science\, Health and Medicine | 
 Pharmaceuticals | Drug Development\n\nPrices:Drug Developer Pricing (Conf
 erence + Pre-Conference Day): USD 4197.00\,Drug Developer Pricing (Confer
 ence Only): USD 2999.00\,Academic Pricing (Conference + Pre-Conference Da
 y): USD 3597.00\,Academic Pricing (Conference Only): USD 2599.00\,Service
  Provider Pricing (Conference + Pre-Conference Day): USD 5197.00\,Service
  Provider Pricing (Conference Only): USD 3799.00\n\nSpeakers: Emma Wang\,
  Chief Technology Officer\, YolTech Therapeutics\, Rajul Jain\, Managing 
 Director\, Vida Ventures\, Anni Chang\, Senior Scientist II\, USP\, Evan 
 Williams\, Professor University of California\, Berkeley\, Isabelle Gusev
 \, Principal Scientist and Group Leader\, Analytical Development\, CMC\, 
 Tessera Therapeutics\, Matthew Reynolds-Tejeda\, Senior Associate Scienti
 st\, Nanoparticle Process Development\, Strand Therapeutics\, Lokesh Nars
 ineni\, Senior Scientist\, Process Sciences\, Scribe Therapeutics\, Dan S
 hores\, Partner\, Rothwell Figg\, Douglas Scott\, Scientist II\, LNP Form
 ulations and Process Development\, Prime Medicine\, Jennifer Zachry\, Co-
 Founder\, Director\, Business Development\, Orion Therapeutics\, Padma Ma
 lyala\, Chief Technology Officer\, nChroma Bio\, Amit Singh\, Director\, 
 Delivery Discovery\, Mote Therapeutics\, Michael Smith\, Director\, Emerg
 ing Technologies\, Moderna\, Roger Adami\, Chief Technology Officer\, Lan
 d Therapeutics\, Zach Zhu\, Chief Technology Officer\, Innorna\, Issi Roz
 en\, General Partner\, Google Ventures\, Mercedes Segura Gally\, Vice Pre
 sident\, Process Development\, Editas Medicine\, Urmi Chheda\, Senior Pro
 cess Engineer\, Editas Medicine\, Andrzej Pitek\, Delivery Expert\, Andre
 w Cornforth\, Chief Technology Officer\, Corner Therapeutics\, Adrian Bot
 \, Scientific\, Executive Officer\, Vice President - Research Development
 \, Capstan Therapeutics\, Arnab Rudra\, Visiting Scientist\, Boston Child
 ren's Hospital\, Morgan Urello\, Principal Scientist\, Nucleic Acid Deliv
 ery\, Biotech Startup\, Delai Chen\, Director\, Nanoparticle Formulation\
 , Beam Therapeutics\, Ronen Eavri\, Chief Executive Officer and Co-Founde
 r\, Barcode Nanotech\, Kinkini Roy\, PhD Associate Director - Drug Produc
 t Development\, Aviceda Therapeutics\, Brenda Star Clemente\, Director\, 
 Drug Product Process Development\, Arcturus Therapeutics\, Shengshuang Zh
 u\, Senior Principal Scientist\, Arbor Biotech\, Jamie Tsung\, Director\,
  Drug Product Formulation\, CMC Development\, Alnylam\, Harsh Chauhan\, D
 irector\, Formulation Development and External Manufacturing\, Alltrna\, 
 Daryl Drummond\, Chief Scientific Officer\, Akagera Medicines\, Bo Ying\,
  Chief Executive Officer\, Abogen Biosciences\, Raquib Hasan\, Senior Sci
 entist\, Advanced Technologies\, Drug Product Development\, Takeda\, Geof
 frey Prevot\, Scientist\, Early Formulation and Drug Profiling\, Servier\
 , Saikat Manna\, Senior Scientist\, Delivery and Formulation\, Sanofi\, N
 atalya Martin\, Principal Scientist\, Sanofi\, Saswata Karmakar\, Directo
 r\, Platform Chemistry\, Sanofi\, Eric Holowka\, Associate Director\, Dru
 g Delivery Innovation\, Regeneron\, Aishwarya Saraswat\, Senior Scientist
 \, Formulation Development Group\, Regeneron\, Shruti Trivedi\, Scientist
 \, Pfizer\, Matt Eastwood\, Scientist II\, Nucleic Acid Delivery\, Novo N
 ordisk\, Hongjing Xia\, Principal Scientist II\, Novartis\, James Deng\, 
 Associate Principal Scientist\, Vaccine Analytical Research and Developme
 nt\, Merck and Co\, Bader Jarai\, Principal Scientist\, Drug Product Deve
 lopment and Delivery\, Johnson and Johnson\, Rushit Lodaya\, Associate Di
 rector\, RNA Delivery Sciences\, GlaxoSmithKline\, Daniel Estabrook\, Sen
 ior Advisor\, Bioproduct Research and Development\, Eli Lilly and Co.\, E
 ster Caffarel-Salvador\, Director\, Strategic Innovation\, Chiesi Global 
 Rare Diseases\, Liping Zhou\, Senior Director\, Advanced Drug Delivery\, 
 AstraZeneca\, Ching Kim Tye\, Head of Lipid Nanoparticle and Platform Dev
 elopment\, Sanofi\, Luis Brito\, Vice President\, Delivery Platform\, Bea
 m Therapeutics\, Annette Bak\, Head of Advanced Drug Delivery\, AstraZene
 ca\n
DTEND:20260408T170000
DTSTAMP:20260515T081643Z
DTSTART:20260406T080000
LOCATION:The Westin Boston Seaport District\, 425\, Summer Street\, Boston
 \, Massachusetts\, 02210\,
SEQUENCE:0
SUMMARY:LNPs continue to dominate the spotlight in biopharma with three la
 ndmark acquisitions in the past six months\, AbbVie/Capstan Therapeutics\
 , Eli Lill...
UID:d371f985-652d-4891-b58d-a59025783d3d
END:VEVENT
END:VCALENDAR